



**SHARP THERPEUTICS CORP. ANNOUNCES RESULTS FROM
ANNUAL MEETING OF SHAREHOLDERS**

PITTSBURGH, PENNSYLVANIA AND TORONTO, July 21, 2025 – Sharp Therapeutics Corp. (TSXV: [SHRX](#)) ("Sharp" or the "Company"), a pre-clinical biotechnology company developing small molecule therapies to treat genetic diseases, is pleased to announce the voting results from its annual general meeting of shareholders held on July 18, 2025 (the "**Meeting**").

All nominees set forth in the Company's management information circular dated June 10, 2025 (the "**Circular**") were elected as directors of the Company at the Meeting.

Detailed results of the votes are set out below:

Nominee	Number of Shares		Percentage of Votes	
	For	Withheld	For	Withheld
Scott Sneddon	10,923,102	0	100 %	0%
William R. Newlin	10,923,102	0	100 %	0%
John L. Brooks III	10,923,102	0	100 %	0%
Dietrich Stephan	10,923,102	0	100 %	0%
John Hathaway	10,923,102	0	100 %	0%
Lorne Sugarman	10,923,102	0	100 %	0%

The Circular also sought approval to re-appoint MNP LLP as auditors of the Company and to authorize the board of directors of the Company to fix the auditors' remuneration. The results of the shareholder votes for this item is set out below:

Motion	Number of Shares For	Percentage of Votes For
Appointment of Auditors	10,923,102	100 %

About Sharp Therapeutics Corp.

First-Choice Therapies for Genetic Diseases

Sharp Therapeutics is a pre-clinical stage company developing first-choice small-molecule therapeutics for genetic diseases. The Company's discovery platform combines novel high throughput screening technologies, with compound libraries computational optimized based on the physics and biology of cellular trafficking defects and allosteric activation of proteins. The platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines.

For additional information on Sharp, please visit: www.sharptx.com.

Contacts:

Scott Sneddon, PhD, JD
Chief Executive Officer
412-206-5303 or scott@sharptx.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.